Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
Global Automatic Activation Devices Market 2020 Growth Opportunities and Competitive Landscape 2025 – Cypres, MarS, Vigil, FXC – KSU | The Sentinel Newspaper
KSU | The Sentinel Newspaper | June 15, 2021
Tofino Hatchery receives $10K donation – Tofino-Ucluelet Westerly News - Tofino
Tofino-Ucluelet Westerly News | June 15, 2021
Brand Battles: Miracle-Gro Aims To Weed Out 'Gromeo' TM
Law360 | June 11, 2021
COVID has filled students with anxiety for the future
The LumberJack | April 29, 2021
Meet The News-Press 2021 Boys Basketball All-Area teams - The News
The News-Press | March 28, 2021
Charles River Laboratories taps Cypre for 3D tumor model research
FierceBiotech | February 2, 2021
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review